The Campus Biotech Lighthouse Partnership for AI-Guided Neuromodulation has successfully completed its first year, marking a significant milestone in its mission to drive disruptive innovation in neuroscience. This inter-institutional collaboration brings together over 60 scientists, engineers, and clinicians with the goal of accelerating translational research and development in neurotechnology and artificial intelligence. By harnessing the interdisciplinary expertise present in the Lemanic Region, the Lighthouse Partnership addresses the increasing global challenge of neurological and mental health disorders with leading institutions such as the Neuro X Institute of EPFL, the Synapsy Centre for Neuroscience and Mental Health research at the University of Geneva, the University Hospitals of Geneva (HUG), and the Lausanne University Hospital (CHUV).
As we gather for the final Lighthouse update meeting of 2024, we reflect on a year filled with significant achievements and milestones. During our first year, the team secured approval for Transcranial Temporal Interference Stimulation (tTIS) in preclinical models, paving the way for groundbreaking translational research. Clinical approval for expanded indications was also obtained, allowing for broader clinical applications and enhancing the potential impact of innovative technologies. A notable achievement was the successful implantation of the second patient with the Digital Bridge system, showing a step forward in clinical neuromodulation.
The team made significant strides in communications, publishing six influential papers in journals like Nature Medicine, Science Advances, and Nature Human Behavior, just to name a few. Additionally, the partnership secured EIC funding for NeuroRestore to leverage the Digital Bridge in the rehabilitation of stroke patients.
Translational achievements included strategic planning for intellectual property related to partnership developed technology, aiming to commercialize our innovative approaches to the treatment of neurological and mental health disorders. We also enhanced our patent portfolio based on advancements in Digital Bridge technology, strengthening our intellectual property assets.
This inaugural year was also marked by the approval of our budgets and the continuation of the program by the Wyss Center Executive Board in November. This endorsement is a testament to the impactful work we are doing.
As we close the year, we look forward to building on these successes and continuing our mission to develop innovative solutions in AI-guided neuromodulation. Thank you to everyone who has contributed to making 2024 a remarkable year for the Lighthouse Partnership. By fostering a multidisciplinary approach and focusing on translational excellence, the institutions of the Lighthouse Partnership are driving innovation from research to market impact. Our 2024 achievements highlight our dedication to advancing neuroscience and neuromodulation, promising a better future for people suffering from neurological and mental health disorders.
More information:
